STE · NYSE · Healthcare
STERIS plc (STE) — Rank #278 by gross profitability (GP/assets 0.24) · ROE 10.9% · Piotroski F-Score 9 / 9.
As-of 2026-10-30 · CIK 0001757898 · all metrics point-in-time as of the filing date.
About
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally.
Show moreShow less
It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015.
STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- L2
- Filer Category
- Large accelerated filer
- Fiscal Year End
- March 31
- Website
- steris.com
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
17,937
Industry
Medical Devices
Exchange
NYSE
12/12
Flags passed
STE passes 12/12 quality flags
- PASSGross margin holding
- PASSDilution within 2%
- PASSFCF not negative from investment
- PASSDisclosure consistent
- PASSRevenue not declining
- PASSOperating margin holding
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSBalance sheet stable
- PASSNo competitive retreat
- PASSSBC not compressing margin
- PASSNo valuation convergence
Strengths Revenue growth accelerating · Operating leverage expanding · Deferred revenue growing
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passFCF yield, shareholder yield, and buyback activity are the primary reads at this stage.
Profitability
Does it make money well?
No warning flags · GP/assets 20th percentile of 41 SIC 38 peers
Gross profitability (GP / assets)
0.24
Primary signal (Novy-Marx).
20th pctl of 41 SIC 38 peers
Return on equity
10.9%
Gross margin
44.2%
30th pctl of 41 SIC 38 peers
Revenue growth (YoY)
8.7%
RPO growth (YoY)
-17.6%
Remaining performance obligations growth — RPO > revenue = forward demand building.
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
9.4%
Revenue CAGR (5Y)
13.8%
Earnings CAGR (3Y)
94.1%
FCF CAGR (3Y)
35.0%
Cash Flow Health
Is the cash real?
No warning flags · FCF 24% above net income
Free cash flow
$972.40M
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
24.3%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.0%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
No warning flags · net debt $1.41B, F-Score 9/9
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.49
64th pctl of 40 SIC 38 peers (best = lowest)
Current ratio
1.91×
18th pctl of 40 SIC 38 peers
Quick ratio
1.17×
Net cash
-$1.41B
Cash & equivalents minus total debt.
Piotroski F-Score
9 / 9
Fundamental-strength score (0-9).
Valuation
Is the price reasonable?
No warning flags
Dividend safety
Composite score
3.8 / 5
Capital allocation quality
Composite score
3.7 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports